Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Non-small cell lung cancer

Non-small cell lung cancer This congress report gives an overview of the most important news concerning lung cancer presented at ASCO 2008 meeting. The most interesting highlights were: (1) For the 1st-line treatment of patients with advanced NSCLC, Cetuximab, added to a platinum-based chemotherapy, sets a new standard and side effects (like acne-like rash) were as expected and manageable. (2) Insulin-like growth factor type I receptor (IGF-IR) in combination with chemotherapy could be an optimistic therapeutic option for NSCLC with squamous cell histology since first results proved a response rate of 72% in this histological subtype. (3) Erlotinib as 1st-line treatment for elderly patients showed encouraging efficacy. (4) For patients without progression after the first line regimen, early introduction of a second line agent is an efficient novel therapeutic option. Further validating studies are warranted. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/non-small-cell-lung-cancer-rj0Wgn7qe1

References (41)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-008-0068-4
Publisher site
See Article on Publisher Site

Abstract

This congress report gives an overview of the most important news concerning lung cancer presented at ASCO 2008 meeting. The most interesting highlights were: (1) For the 1st-line treatment of patients with advanced NSCLC, Cetuximab, added to a platinum-based chemotherapy, sets a new standard and side effects (like acne-like rash) were as expected and manageable. (2) Insulin-like growth factor type I receptor (IGF-IR) in combination with chemotherapy could be an optimistic therapeutic option for NSCLC with squamous cell histology since first results proved a response rate of 72% in this histological subtype. (3) Erlotinib as 1st-line treatment for elderly patients showed encouraging efficacy. (4) For patients without progression after the first line regimen, early introduction of a second line agent is an efficient novel therapeutic option. Further validating studies are warranted.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jan 1, 2008

There are no references for this article.